COMPASS Pathways PLC (CMPS)

NASDAQ: CMPS · IEX Real-Time Price · USD
10.27
-0.11 (-1.06%)
Jun 29, 2022 11:47 AM EDT - Market open
-1.06%
Market Cap 436.59M
Revenue (ttm) n/a
Net Income (ttm) -80.20M
Shares Out 42.51M
EPS (ttm) -1.94
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 56,304
Open 10.44
Previous Close 10.38
Day's Range 10.04 - 10.44
52-Week Range 6.54 - 49.52
Beta n/a
Analysts Buy
Price Target 69.36 (+575.4%)
Earnings Date Aug 10, 2022

About CMPS

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Ki... [Read more...]

Industry Health Care Providers & Services
IPO Date Sep 18, 2020
Employees 116
Stock Exchange NASDAQ
Ticker Symbol CMPS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 17 analysts, the average rating for CMPS stock is "Buy." The 12-month stock price forecast is 69.36, which is an increase of 575.37% from the latest price.

Price Target
$69.36
(575.37% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Wall Street Analysts See a 781% Upside in COMPASS Pathways PLC Sponsored ADR (CMPS): Can the Stock Really Move This H...

The average of price targets set by Wall Street analysts indicates a potential upside of 781.4% in COMPASS Pathways PLC Sponsored ADR (CMPS). While the effectiveness of this highly sought-after metric i...

COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting

Positive data from phase IIb study shows potential of COMP360 psilocybin therapy in treatment-resistant depression

COMPASS Pathways to participate in upcoming Citi's Biopharma Virtual Co-Panel Day and H.C. Wainwright Global Investme...

LONDON, May 12, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announc...

COMPASS Pathways plc announces first quarter 2022 financial results and business highlights

LONDON, May 10, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental hea...

COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults

London, UK – 9 May 2022

COMPASS Pathways plc to announce first quarter 2022 financial results on 10 May 2022

LONDON, May 03, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announc...

COMPASS Pathways to participate in Needham Healthcare conference

LONDON, April 04, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, annou...

COMPASS Pathways and partners launch The Centre for Mental Health Research and Innovation, in the UK

Pioneering c ollaboration with King's College London and South London and Maudsley NHS Foundation Trust

COMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business highlights

LONDON, United Kingdom, Feb. 24, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovat...

COMPASS Pathways plc to announce fourth quarter and full year 2021 financial results on 24 February 2022

LONDON, United Kingdom, Feb. 17, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in menta...

COMPASS Pathways to participate in H.C. Wainwright investor conference

LONDON, Jan. 10, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announ...

COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology

Study demonstrates feasibility of simultaneous administration of COMP360 psilocybin  in a controlled setting to healthy participants with 1:1 therapist support

3 Psychedelic Stocks to Play the Shroom Boom

Psychedelic substances are often grouped together with cannabis, but there are some important distinctions. ATAI, CMPS and FTRP are some of the best stocks in the space.

Other symbols: ATAIFTRP

Psychedelics Company COMPASS Pathways To Join NASDAQ Biotechnology Index

Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ:CMPS) revealed Friday that it has been selected for addition to the Nasdaq Biotechnology Index (NASDAQ:NBI), effective as of ma...

COMPASS Selected for Addition to NASDAQ Biotechnology Index

London, U.K., Dec. 17, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, ...

COMPASS Pathways announces changes in Executive Team

M atthew Owen s appointed General Counsel and Chief Legal Officer ;

Psilocybin Therapy Combined With SSRI Antidepressants Is Possible, COMPASS Study Confirms

Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ:CMPS) announced Monday it had achieved positive results from its exploratory study of COMP360 psilocybin therapy in conjunction...

Michael Falvey joins COMPASS Pathways as Chief Financial Officer

London, UK - 3 December 2021

COMPASS Pathways: Positive Psilocybin Trial, High-Dose Group Improves Beyond Depression Reduction

As COMPASS Pathways (NASDAQ: CMPS) crunches more data from a recent trial investigating psilocybin therapy for treatment-resistant depression (TRD), findings show that a higher dose of 25mg (compared to...

COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 ps...

- Positive topline results validated by additional analyses

COMPASS Pathways to participate in upcoming Evercore, H.C. Wainwright & Berenberg investor conferences

LONDON, Nov. 30, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announ...